features: Ovarian Cancer

Sig3 mutation and immune score determine responses to combination PARP and PD-1 inhibition in ovarian cancer

Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception….

Read More

NHS approval for ovarian cancer drug, olaparib

Olaparib, a maintenance therapy for ovarian cancer, may prolong the benefit of initial treatment in BRCA1/2 mutated ovarian cancer patients…

Read More
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals